Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABP-745 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| ABP-745 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABP-745 | DRUG | 0.5, 5 or 25 mg tablet |
| Placebo | DRUG | Placebo tablet |
Inclusion Criteria: * Healthy male or female volunteers, aged 18 and 55 years (inclusive) at the time of signing the informed consent form (ICF). * Body mass index (BMI) range within 18 \~ 30 kg/m2 (inclusive), and body weight of ≥ 50.0 kg for male and ≥ 45.0 kg for female. * Generally healthy base...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Amgen Inc. | AMGN | 1 | PHASE3 | Pegloticase, Methotrexate |
| Protalix BioTherapeutics, Inc. (DE) | PLX | 1 | PHASE2 | PRX-115, Methotrexate |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | PHASE1 | NNC4004-0002 |
| TJ Biopharma Co., Ltd. | IMAB | 1 | PHASE2 | Plonmarlimab, Compound betamethasone |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE1 | Pegylated Recombinant Candida Utilis Uricase |
ABP-745 is an investigational small molecule being developed for the treatment of gout, including acute gout flares. It is currently in Phase 1 clinical development and is not yet approved by the FDA. The drug is being studied for its safety, tolerability, and pharmacokinetics in healthy volunteers.
ABP-745 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The drug is currently in Phase 1 clinical development for the treatment of gout and gout flares.
ABP-745 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 study of the drug has been completed, evaluating its safety, tolerability, and pharmacokinetics in healthy volunteers.
ABP-745 has one completed Phase 1 clinical trial, identified as NCT06258213. This study evaluated the safety, tolerability, and pharmacokinetics of oral ABP-745 in healthy volunteers in the United States. The trial enrolled 90 participants and was randomized, double-blind, and placebo-controlled.
ABP-745 is a distinct investigational drug candidate developed by cbdMD, Inc. It is not known to be the same as any other approved or marketed medication. It is being studied specifically for the treatment of gout and acute gout flares.